Low-molecular-weight heparin prophylaxis against thromboembolism after total hip replacement--the never-ending story?
Dahl
O E
OE
Bergqvist
D
D
Cohen
A T
AT
Frostick
S P
SP
Hull
R D
RD
D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D019644:Arthroplasty, Replacement, Hip / Q000009:adverse effects* / Q000191:economics*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D017048:Health Care Costs; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects / Q000191:economics* / Q000627:therapeutic use*; D006801:Humans; D015994:Incidence; D010690:Phlebography; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology; D013923:Thromboembolism / Q000000981:diagnostic imaging / Q000191:economics / Q000453:epidemiology / Q000209:etiology* / Q000517:prevention & control*; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use; D014945:Wound Healing / Q000187:drug effects
D000925:Anticoagulants; D006495:Heparin, Low-Molecular-Weight; D014859:Warfarin